Protalix BioTherapeutics (PLX) EBITDA (2010 - 2026)

Protalix BioTherapeutics has reported EBITDA for 17 years, with the latest figure at $4.8 million in Q2 2026.

• On a quarterly basis, EBITDA rose 272.69% year-over-year to $4.8 million in Q2 2026; TTM through Jun 2026 was $24.6 million, a 162.87% increase from a year earlier, with the FY2025 full-year figure at -$4.0 million, down 177.28% from the prior year.
• EBITDA was $4.8 million for Q2 2026 at Protalix BioTherapeutics, down from $21.6 million in the prior quarter.
• The five-year high for EBITDA was $21.6 million in Q1 2026, with the low at -$5.6 million in Q4 2023.
• Average EBITDA over 5 years is $1.4 million, with a median of -$2.0 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: EBITDA slumped 156.62% in 2025, then soared 667.25% in 2026.
• Over 5 years, EBITDA stood at -$2.5 million in 2022, then slumped by 125.05% to -$5.6 million in 2023, then jumped by 234.34% to $7.5 million in 2024, then tumbled by 156.62% to -$4.3 million in 2025, then surged by 212.48% to $4.8 million in 2026.
• The last three EBITDA figures came in at $4.8 million (Q2 2026), $21.6 million (Q1 2026), and -$4.3 million (Q4 2025), per Business Quant data.